Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038927 | 0.92 | CCR4 (0.49) | CCR4NAMPTPKMSCN9APOLB | |
| SCHEMBL6038813 | 0.90 | CCR4 (0.52) | CCR4NAMPTSCN9APOLB | |
| SCHEMBL6038468 | 0.89 | CCR4 (0.47) | CCR4NAMPTSCN9APOLB | |
| SCHEMBL6038387 | 0.89 | CCR4 (0.47) | CCR4NAMPTSCN9APOLB | |
| SCHEMBL6038792 | 0.88 | CCR4 (0.47) | CCR4NAMPTSCN9A | |
| SCHEMBL6038775 | 0.88 | CCR4 (0.47) | CCR4NAMPTSCN9APOLB | |
| SCHEMBL6038976 | 0.88 | CCR4 (0.50) | CCR4NAMPTSCN9APOLB | |
| SCHEMBL6038916 | 0.87 | CCR4 (0.49) | CCR4NAMPTSCN9APOLB | |
| SCHEMBL6038479 | 0.87 | POLB (0.49) | CCR4SCN9APOLB | |
| SCHEMBL6038816 | 0.87 | CCR4 (0.50) | CCR4SCN9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | CCR4 1/4885NAMPT 2390/4885PKM 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.